Impact of radiotherapy on survival rates in chemotherapy treated non small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009
C-erbB-3 expression in non small cell lung cancer (NSCLC) patients treated by erlotinib Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Impact of radiotherapy on survival rates in chemotherapy treated small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009
Rates of treatment response and median survival in advanced non small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
Combination of erlotinib and bevacizumab in non small cell lung cancer patients Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Gefitinib in the non small cell lung cancer treatment: contribution to prolongation and quality of survival Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004
Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009
Long-term survival of the patients with advanced non small cell lung carcinomas after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
Cancer recurrence in surgically treated non small cell lung cancer (NSCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 755s Year: 2006
The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004
Early concurrent chemoradiotherapy for limited small cell lung cancer (LSCLC). Analysis of toxicity and survival of 30 consecutive patients Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002
Small cell lung cancer patients and their responses to treatment Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019
Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011
Second-line treatment patients at relapse of disseminated small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 395s Year: 2001
Endoscopical laser treatment in combined therapy non small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002
Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002